Press Release



BROOKLYN, NY (April 25, 2021) — Prescription Justice strongly supports the re-introduction of the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3). If enacted into law, it will end the crisis of high drug prices in America while adding new targeted public financing for pharmaceutical innovation. On behalf of the Prescription Justice Board of Directors, Gabriel Levitt stated:

“This robust, comprehensive legislation will empower Medicare to effectively negotiate drug prices with pharmaceutical companies; crack down on price gouging; cap the amount that older Americans pay for drugs; and increase public financing of pharmaceutical innovation.” 

“H.R. 3 should appeal to voters across the political spectrum. Republicans and Democrats are more unified on drug prices than on any other issue. In our Congressional Report Card on Drug Prices, voting for H.R. 3 noticeably increased the grades of House members. For the most part, Republicans ignored the wishes of their constituents by voting against H.R. 3 in 2019. We look forward to working with them to garner more support this time around.” 

“In keeping with our policy platform, Prescription Justice recommends amending the bill to expressly permit individuals to personally import medicine from other high-income countries with strong pharmaceutical standards and lower pharmacy prices. As currently drafted, H.R. 3 may leave cash prices for the uninsured or underinsured  prohibitively high. Safe personal imports will help those Americans still falling through the cracks of our healthcare system afford needed medications.” 

About Prescription Justice

Prescription Justice, a 501c4 nonprofit organization, is dedicated to ending the crisis of high drug prices in America. Bringing together doctors, lawyers, public health and consumer advocates, and concerned citizens from across party lines, Prescription Justice advocates for serious regulatory and legislative reforms that will substantially lower the cost of prescription drugs for all Americans and expand access to lower-cost medication from abroad. Learn more at:


Stay informed about news and advocacy centered on the crisis of high drug prices